Cost-effectiveness watchdog NICE has recommended routine NHS use of two new therapies for women with advanced breast cancer – Gilead's Trodelvy and Novartis' Piqray – in England.
The impact of cancer on both patients and their families cannot be overstated, but new figures show that more people than ever will be living with cancer by the end of 2025. According to analysis of ...
NHS England has started a pilot trial of an iPhone app and device combination that could be used by nursing ... some types of breast, ovarian, prostate, and pancreatic cancer, and GRAIL's Galleri ...
IN the recent past, cancer was referred to as “the c word” or “the big c.” Thankfully, the positive work of many cancer charities, research units and the medical profession mean that this disease, ...